{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:28:05Z","timestamp":1769740085757,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016669","name":"Sj\u00f6berg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02441"],"award-info":[{"award-number":["2018-02441"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2018-418"],"award-info":[{"award-number":["CAN2018-418"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006738","name":"Medicinska Fakulteten, Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish National Health Service, ALF"},{"DOI":"10.13039\/501100019970","name":"Lennart Glans Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019970","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BioCARE"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the \u201cChemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)\u201d study aims to monitor these processes to gain new insight into this perplexing disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The CHAMP study is a prospective, single-arm observational study. All patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the Department of Oncology, Sk\u00e5ne University Hospital, are invited to participate. Clinical and pathological data will be compiled at study entry. A single tissue microarray (TMA) block is constructed for each patient with a resected tumour and blood samples are drawn before, during and after chemotherapy in order to sample peripheral blood mononuclear cells (PBMC), cytokines and circulating tumour DNA (ctDNA). Next generation sequencing will be performed on tumour tissue and ctDNA to detect changes in the clonal landscape over space and time.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>Despite the recent emergence of some promising biomarkers for periampullary cancer, there has been a lack of success in clinical implementation. Cancer cells continuously adapt and become resistant to treatment during chemotherapy. To be able to keep pace with and hopefully overtake this rapid evolution we must, with the help of new diagnostic tools, be ready to adapt and alter treatment accordingly. It seems to us that the only way forward is to gain a better understanding of the dynamics of the disease during treatment. With insights gained from the CHAMP study we hope to find answers to key questions in this largely unexplored territory.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>This study has been registered 30th October 2018 at clinicaltrials.gov as <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03724994\">NCT03724994<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-06807-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:03:53Z","timestamp":1586955833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study"],"prefix":"10.1186","volume":"20","author":[{"given":"Sofie Olsson","family":"Hau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Nodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emelie","family":"Karnevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Boman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Williamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Leandersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gisselsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Heby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"18","key":"6807_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"19","key":"6807_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"15","key":"6807_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-17-0162","volume":"23","author":"ES Knudsen","year":"2017","unstructured":"Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers. Clin Cancer Res. 2017;23(15):4429\u201340.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"6807_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-16-2411","volume":"23","author":"SB Dreyer","year":"2017","unstructured":"Dreyer SB, Chang DK, Bailey P, Biankin AV. Pancreatic Cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23(7):1638\u201346.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6807_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"6807_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrc3298","volume":"12","author":"RJ Gillies","year":"2012","unstructured":"Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"6807_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast Cancer delineated by single-cell sequencing. Cell. 2018;173(4):879\u201393 e13.","journal-title":"Cell."},{"key":"6807_CR8","doi-asserted-by":"crossref","unstructured":"Sakamoto H, Attiyeh MA, Gerold JM, Makohon-Moore AP, Hayashi A, Hong J, et al. The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discov. 2020. Epub ahead of print.","DOI":"10.1158\/2159-8290.CD-19-1508"},{"issue":"1","key":"6807_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/0008-5472.CAN-15-3024","volume":"76","author":"DR Welch","year":"2016","unstructured":"Welch DR. Tumor heterogeneity--A 'Contemporary Concept' founded on historical insights and predictions. Cancer Res. 2016;76(1):4\u20136.","journal-title":"Cancer Res"},{"issue":"7467","key":"6807_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338\u201345.","journal-title":"Nature."},{"issue":"1","key":"6807_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1373\/clinchem.2012.188557","volume":"59","author":"C Gasch","year":"2013","unstructured":"Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS\/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2013;59(1):252\u201360.","journal-title":"Clin Chem"},{"issue":"7655","key":"6807_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351.","journal-title":"Nature."},{"issue":"1","key":"6807_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","volume":"23","author":"D Pietrasz","year":"2017","unstructured":"Pietrasz D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, et al. Plasma circulating tumor DNA in pancreatic Cancer patients is a prognostic marker. Clin Cancer Res. 2017;23(1):116\u201323.","journal-title":"Clin Cancer Res"},{"key":"6807_CR14","doi-asserted-by":"crossref","unstructured":"Wartenberg M, Cibin S, Zlobec I, Vassella E, Eppenberger-Castori S, Terracciano L, et al. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic\/Predictive Significance. Clin Cancer Res. 2018;24(18):4444\u201354.","DOI":"10.1158\/1078-0432.CCR-17-3401"},{"issue":"7749","key":"6807_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385.","journal-title":"Nature."},{"issue":"22","key":"6807_CR16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung Cancer. N Engl J Med. 2017;376(22):2109\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"6807_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell. 2018;173(3):595\u2013610 e11.","journal-title":"Cell."},{"issue":"4","key":"6807_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.5026","volume":"244","author":"A Mezheyeuski","year":"2018","unstructured":"Mezheyeuski A, Bergsland CH, Backman M, Djureinovic D, Sjoblom T, Bruun J, et al. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. J Pathol. 2018;244(4):421\u201331.","journal-title":"J Pathol"},{"issue":"6030","key":"6807_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","volume":"332","author":"SC Bendall","year":"2011","unstructured":"Bendall SC, Simonds EF, Qiu P, el AD A, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687\u201396.","journal-title":"Science."},{"issue":"7","key":"6807_CR20","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41588-018-0131-y","volume":"50","author":"J Karlsson","year":"2018","unstructured":"Karlsson J, Valind A, Holmquist Mengelbier L, Bredin S, Cornmark L, Jansson C, et al. Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer. Nat Genet. 2018;50(7):944\u201350.","journal-title":"Nat Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06807-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:42:04Z","timestamp":1618443724000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06807-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6807"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06807-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients are given study information by their oncologist and research nurse and, if they choose to participate, they are to give their informed, written consent. The treatment regimen will follow Swedish national guidelines and will not be affected by the study.Permission for the study has been obtained from the Ethics Committee of Lund University in January 2018 (ref nr 2018\u201313). The study protocol complies with the Helsinki declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"308"}}